Get the Stockscreener App
4.16
1.87%
-0.11
Edesa Biotech Inc stock is traded at $4.16, with a volume of 454.38K.
It is down -1.87% in the last 24 hours and up +274.11% over the past month.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
See More
Previous Close:
$4.27
Open:
$4.35
24h Volume:
454.38K
Relative Volume:
0.15
Market Cap:
$33.89M
Revenue:
-
Net Income/Loss:
$-7.82M
P/E Ratio:
-3.6284
EPS:
-1.1465
Net Cash Flow:
$-8.00M
1W Performance:
+170.32%
1M Performance:
+274.11%
6M Performance:
+65.61%
1Y Performance:
+84.58%
1-Day Range:
$3.81
$4.53
1-Week Range:
$1.51
$5.399
52-Week Range:
$0.72
$5.399
Edesa Biotech Inc Stock (EDSA) Company Profile
Name
Edesa Biotech Inc
Sector
Industry
Phone
(905) 475-1234
Address
100 SPY COURT, MARKHAM, ON
Compare EDSA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
4.06 | 35.65M | 0 | -7.82M | -8.00M | -1.1465 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.48 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
734.61 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.00 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Edesa Biotech Inc Stock (EDSA) Latest News
FY2026 EPS Forecast for Edesa Biotech Decreased by Analyst - Defense World
Point72 group (NASDAQ: EDSA) reports 600,000 shares, 7.2% stake - Stock Titan
Velan Capital details Edesa Biotech (NASDAQ: EDSA) 9.99% stake - Stock Titan
Nijhawan group boosts Edesa Biotech (EDSA) stake to 19.99% in 13D/A - Stock Titan
Edesa Biotech (NASDAQ: EDSA) CEO adds 50,571 shares in open-market buys - Stock Titan
[Form 4] Edesa Biotech, Inc. Insider Trading Activity - Stock Titan
EDSA: Strengthened Phase 3 ARDS Data Shows Significant Reduction in 28-Day Mortality - Yahoo Finance
Edesa Biotech Advances with Promising Phase 3 Outcomes - StocksToTrade
Edesa Biotech’s Paridiprubart Phase 3 Success Drives Optimism - timothysykes.com
Edesa Biotech’s Strategic Advances Boost Stock Outlook - StocksToTrade
Edesa Biotech Surpasses Expectations with Promising Phase 3 Data - timothysykes.com
EDSA Technical Analysis & ETF Price Forecast - Intellectia AI
Why Is Edesa Biotech, Inc. (EDSA) Stock Up Today? - Meyka
Why Did EDSA Stock Rally More Than 70% Today? - Asianet Newsable
Biotech Stock Edesa Biotech (Nasdaq:EDSA) Gains on News of Additional Positive Results from Phase 3 Paridiprubart Study - Investorideas.com
Edesa Biotech stock surges on positive Phase 3 trial data By Investing.com - Investing.com Canada
Edesa Biotech stock surges on positive Phase 3 trial data - Investing.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Edesa Biotech reports mortality reduction in phase 3 trial By Investing.com - Investing.com Australia
Edesa Biotech Reports Positive Phase 3 Paridiprubart Results - TipRanks
Edesa Biotech reports mortality reduction in phase 3 trial - Investing.com
Edesa Biotech reports additional results from phase 3 paridiprubart study - marketscreener.com
Edesa Biotech shows significant 28-day mortality reduction in 278-patient Phase 3 study - TradingView
Mortality-cutting Phase 3 data boost Edesa Biotech (NASDAQ: EDSA) - Stock Titan
Edesa Biotech Reports Additional Results From Phase 3 Paridiprubart Study - TradingView
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study - GlobeNewswire
Update Recap: Can Edesa Biotech Inc expand into new marketsMarket Trend Review & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Edesa Biotech reports FQ1 net loss of $2.2 million - MSN
Will Edesa Biotech Inc. stock benefit from infrastructure spending2025 Earnings Surprises & Accurate Technical Buy Alerts - mfd.ru
Edesa Biotech Inc. (EDSA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Edesa Biotech, Inc. SEC 10-Q Report - TradingView
Edesa Biotech Reports Fiscal 1st Quarter 2026 Results - Bitget
Edesa Biotech (Nasdaq: EDSA) widens loss as R&D spending climbs - Stock Titan
Edesa Biotech, Inc. Reports Q1 2026 Financial Results and Updates on Clinical Programs for EB06 and Paridiprubart - Quiver Quantitative
Canada's Edesa Biotech Q1 net loss widens - TradingView
Can Edesa Biotech Inc. expand into new markets2025 Technical Patterns & Expert Verified Movement Alerts - mfd.ru
Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025 - marketscreener.com
Gains Recap: Does Edesa Biotech Inc have pricing power2025 Historical Comparison & Risk Controlled Swing Alerts - baoquankhu1.vn
Bull Run: Does Edesa Biotech Inc have pricing powerBear Alert & Free Community Consensus Stock Picks - baoquankhu1.vn
Price Action: Is Edesa Biotech Incs growth already priced inJuly 2025 Technicals & Low Risk Growth Stock Ideas - baoquankhu1.vn
Fed Meeting: Can Edesa Biotech Inc sustain earnings growth2025 Top Decliners & Growth Focused Entry Point Reports - baoquankhu1.vn
Bearish Setup: Is PennantPark Investment Corporation a play on infrastructure spendingWeekly Trend Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Buy Signal: Can Edesa Biotech Inc expand into new marketsWeekly Gains Summary & Entry Point Strategy Guides - baoquankhu1.vn
Energy Moves: Is Edesa Biotech Incs growth already priced inJuly 2025 Reactions & Smart Allocation Stock Tips - baoquankhu1.vn
Does Edesa Biotech Inc stock benefit from AI growthEarnings Overview Report & Safe Entry Trade Reports - baoquankhu1.vn
Shorts Report: Will Edesa Biotech Inc stock gain from government policiesMarket Risk Analysis & Accurate Intraday Trade Tips - Bộ Nội Vụ
Is Edesa Biotech Inc. stock positioned for digital transformationShare Buyback & Stepwise Trade Execution Plans - Улправда
Why Edesa Biotech Inc. stock could be next big winnerDaily Trainer Picks & quick comparison of popular models - Улправда
Is Edesa Biotech Inc. stock vulnerable to regulatory risksMarket Performance Recap & Free Reliable Trade Execution Plans - Улправда
Edesa Biotech, Inc.Common Shares (NQ: EDSA - FinancialContent
Published on: 2026-01-06 14:04:13 - ulpravda.ru
Edesa Biotech Inc Stock (EDSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):